Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax Inc (NVAX)

NASDAQ
Currency in USD
Disclaimer
4.78
-0.07(-1.44%)
Closed
After Hours
4.790.00(0.10%)

NVAX Price Commentary

buy its jackpot time next stop 290
If the vaccination route is overtaken by a single pill it will have a negative impact for NVAX and MRNA Assuming the pill is not FDA approved can see by year end NVAX breaking through $300.
this gonna big 300 next stop
Never lose faith in this stock. Gonna be the next big vax!
surprise ... down for financial and another down on Monday I guess
Why surprise ??
surprise surprise... down for financials and another down on Monday I guess
One of the best stocks to get.. Will easily rise to 300 with the EU deal.
Modernas current market capitalisation is 10x that of Novavax.. inderatand they got a head start but given the results and based on the deal with EU, suggests filing for regulatory approval is imminent. Post approval novavax have a vaccine that is at least as good and also have a stage 3 flu vaccine as good or better than anything on the market. So combo flu / covid boosters = advantage novavax at current valuations.
Novavax unable to get approval from any country so far. Only trials that say 90% effective but no approval as production process not ironed out. Q1 approval application delayed to Q3 already. 2021 sales of vaccine in doubt.
They’ve already signed purchase agreement for 270 odd mllion in developed countries and over a billion for low and middle income. So not sure sales will be an issue.
Not denying that they have orders but question is one of delivery. Maybe 2022 will be when they can start but till regulatory approvals start coming later this year, they remain behind the curve of other vax providers.
NEJM.ORG announce Novax is safe !!
Korea Drug and Food Safety official just before confirmed again they are now pre-reviewing the clinical trial data and will rapidly proceed the approval process as soon as SK Biosciense/NVAX submit their P3 approval documents regardless of the NVAX's filing plan in Q3 for FDA, MHRA and EMA.
Korean government said this morning (May 12th in Korea time) they have no change with the existing rollout and admin plans of NVAX vaccine in Korea as Korean FDA is now reviewing the NVAX's clinical trial data submitted by SK Bioscience in parallel with and/or independent of FDA, MHRA and EMA.SK Biosciense now keeps their validation (It might seem to have been completed as they said last month their validation vaccine could be used for commercial purpose.) or commercial operation going and plans to commercially rollout 30m doses of the NVAX vaccine this year and another 10m doses in the early of next year to start to provide them to Korean government from June or July of this year. Korea Ministry of Food and Drug Safety is likely to approve the NVAX jab firstly in the world in next month as Korea President, Mr. Moon announced Monday (May 10) Korea government seems to move up their jab inoculation plan which is to achieve the herd immunity by November. It seems Korea government knows something that the US P3 results would NOT be different from the UK P3 results. Let's see what will happen soon....
So is there an expectation on when they will approve?
dud
Not sure how you work that out. Highest efficacy of all the vaccines against the original strain. Their technology also delivered the first malaria vaccine over 75 percent efficacy in a recent trial and its late stafe flu vaccine is as good or better than anything currently on the market. The only duds are the morons currently panic selling on the eve of approvals and a supply agreement with the EU.
the support is coming at 140
Cant understand the selloff with approvals pending. Makes no sense.
Guess the Company History with failed drug research does not help. However if they get FDA approval ( late April ?)they could soar to $400 plus.
Court case. Great!
Please clarify - what court case ?
1.1billion vaccine deal for nvax announced this evening
I bought share per 328, can I hold or sell now please advise
Biden says USA will have sufficient vaccines for all adults by end May. Nvax not due for approval before early May so stock now less solid as recent sell off confirms.
Are you still holding it
yes..holding some for positive results
The day to hit 300
Starting to fet itritated by all the press releases saying although Moderna and Pfizer vaccines are more efficacious.. i might be missing somethung but did their trial not report against the initial strain... and theyve acknowledged that there caccine wont be as effective afainst the new strain... comparing apples with apples novavax on UK trials reported 95.6 percent efficacy against the original strain.. so on that comparison is it not the highest efficacy against that strain.. and the other strains are still an efficacy question mark for the others?
Your comment appears contradictory. Are you saying NVAX better than, equal to or less efficient than MRNA or PFE
Not sure how that is contradictory. Morderna’s and pfifers results are based on original strain. I believe their efficacy was around 94 percent and up to 90 percent respectively. Like for like against the original strajn nvax confirmed theirs to be 95.6 percent against the original strain. So not sure how thats inferior. Both moderna and pfizer have said theres would be leas effective against the new strain, but they dont have data as to what this is. Novavax does and its 89.3 percent efficacy combined strains. So sating its inferior is lazy jourbalism.
Ok now clearer; got out at $325 a few days ago near ATH.May buy back if price retreats further. On paper it should be now a stronger stock than MRNA as its vaccine potential still to come ( hopefully).
It can go to 300 in days or today
On fire
👏
I saw the news that Novavax doing 3rd phase in US. Tampa General Hospital volunteer on the vaccine 3rd phase trial. Anyone heard that?
300 by Xmas
https://www.gov.uk/government/news/government-invests-in-uk-developed-antibody-tests-from-uk-rapid-test-consortium
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.